Variant Bio
Variant Bio develops therapies by studying the genes of people with exceptional health-related traits. It uses insights from human genetics to inform drug discovery and development, aiming to improve global health while prioritizing ethical partnerships and benefit-sharing with participating communities.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2018
- Employees
- 38
- Stage
- startup
- Members see funding amounts. .
- Founders
- Stephane Castel, PhD
Is this your organization? Claim it
Seattle Genomics Startup Variant Bio Secures Up to $50M Deal with Novo Nordisk to Study Metabolic Diseases Using Diverse Genomic Data
Seattle-based Variant Bio has partnered with Novo Nordisk in a multi-year deal worth up to $50 million to study metabolic diseases using genomic data from diverse populations. The collaboration aims to discover novel drug targets for diseases like obesity and diabetes by leveraging genetic data from globally diverse and underrepresented groups.
People
-
Stephane Castel Founder, Chief Technology Officer & Chief Scientific Officer
-
Andrew Farnum Executive, Chief Executive Officer
-
Craig Basson Executive, Chief Medical Officer, President of R&D